[{"address1": "9713 Key West Avenue", "address2": "Suite 400", "city": "Rockville", "state": "MD", "zip": "20850", "country": "United States", "phone": "301 944 1700", "website": "https://www.maxcyte.com", "industry": "Medical Devices", "sector": "Healthcare", "longBusinessSummary": "MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.", "fullTimeEmployees": 143, "companyOfficers": [{"maxAge": 1, "name": "Mr. Maher  Masoud", "age": 48, "title": "President, CEO & Executive Director", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 650984, "exercisedValue": 0, "unexercisedValue": 430186}, {"maxAge": 1, "name": "Mr. Douglas Arthur Doerfler", "age": 67, "title": "Founder", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 2338348, "exercisedValue": 0, "unexercisedValue": 4022443}, {"maxAge": 1, "name": "Mr. Douglas J. Swirsky CFA, CPA", "age": 54, "title": "Chief Financial Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 607416, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jay  Gelfman", "title": "Senior Vice President of Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ronald Evan Holtz CPA, Ph.D.", "age": 65, "title": "Executive Vice President of Administration", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 649385, "exercisedValue": 0, "unexercisedValue": 6397638}, {"maxAge": 1, "name": "Mr. David  Sandoval", "age": 45, "title": "Senior Vice President, General Counsel & Corporate Secretary", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas Michael Ross", "age": 62, "title": "Executive Vice President of Global Sales", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jack  Horgan", "title": "Vice President of Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jill  Mayer", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. J. Stark Thompson Ph.D.", "age": 81, "title": "Consultant", "yearBorn": 1942, "fiscalYear": 2023, "totalPay": 84708, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.9, "open": 3.92, "dayLow": 3.87, "dayHigh": 4.13, "regularMarketPreviousClose": 3.9, "regularMarketOpen": 3.92, "regularMarketDayLow": 3.87, "regularMarketDayHigh": 4.13, "beta": 1.134, "forwardPE": -9.9, "volume": 181016, "regularMarketVolume": 181016, "averageVolume": 499572, "averageVolume10days": 343870, "averageDailyVolume10Day": 343870, "bid": 3.95, "ask": 3.98, "bidSize": 200, "askSize": 200, "marketCap": 456065280, "fiftyTwoWeekLow": 2.45, "fiftyTwoWeekHigh": 5.545, "priceToSalesTrailing12Months": 10.036869, "fiftyDayAverage": 4.2824, "twoHundredDayAverage": 4.483775, "currency": "USD", "enterpriseValue": 271045920, "profitMargins": -0.77973, "floatShares": 96115646, "sharesOutstanding": 105089000, "sharesShort": 3828612, "sharesShortPriorMonth": 4191757, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0364, "heldPercentInsiders": 0.01447, "heldPercentInstitutions": 0.75481004, "shortRatio": 9.92, "shortPercentOfFloat": 0.0367, "bookValue": 2.111, "priceToBook": 1.8758881, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -35430000, "trailingEps": -0.34, "forwardEps": -0.4, "enterpriseToRevenue": 5.965, "enterpriseToEbitda": -6.466, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "MXCT", "underlyingSymbol": "MXCT", "shortName": "MaxCyte, Inc.", "longName": "MaxCyte, Inc.", "firstTradeDateEpochUtc": 1627651800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "99edb1ce-9d5d-37b7-967d-699d6c90ba1a", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.96, "targetHighPrice": 11.0, "targetLowPrice": 7.0, "targetMeanPrice": 9.25, "targetMedianPrice": 9.5, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 157330000, "totalCashPerShare": 1.497, "ebitda": -41916000, "totalDebt": 18528000, "quickRatio": 13.19, "currentRatio": 14.309, "totalRevenue": 45439000, "debtToEquity": 8.374, "revenuePerShare": 0.437, "returnOnAssets": -0.1107, "returnOnEquity": -0.1533, "freeCashflow": -12644075, "operatingCashflow": -22655000, "revenueGrowth": 0.153, "grossMargins": 0.88431, "ebitdaMargins": -0.92247003, "operatingMargins": -1.14757, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]